ベーチェット病治療法の世界市場2019-2023...市場調査レポートについてご紹介

【英文タイトル】Behcet's Disease Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Small molecules – Market size and forecast 2018-2023
• Biologics – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie Inc.
• Amgen Inc.
• Celgene Corp.
• Eisai Co. Ltd.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services Inc.
• Mylan NV
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Co. Ltd.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Small molecules – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Small molecules – Year-over-year growth 2019-2023 (%)
Exhibit 22: Biologics – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Biologics – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America – Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Drug designations
Exhibit 43: Side effects of small molecule-based drugs used for treatment of Behcet’s disease
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: AbbVie Inc. – Vendor overview
Exhibit 51: AbbVie Inc. – Business segments
Exhibit 52: AbbVie Inc. – Organizational developments
Exhibit 53: AbbVie Inc. – Geographic focus
Exhibit 54: AbbVie Inc. – Key offerings
Exhibit 55: AbbVie Inc. – Key customers
Exhibit 56: Amgen Inc. – Vendor overview
Exhibit 57: Amgen Inc. – Product segments
Exhibit 58: Amgen Inc. – Organizational developments
Exhibit 59: Amgen Inc. – Geographic focus
Exhibit 60: Amgen Inc. – Key offerings
Exhibit 61: Amgen Inc. – Key customers
Exhibit 62: Celgene Corp. – Vendor overview
Exhibit 63: Celgene Corp. – Business segments
Exhibit 64: Celgene Corp. – Organizational developments
Exhibit 65: Celgene Corp. – Geographic focus
Exhibit 66: Celgene Corp. – Key offerings
Exhibit 67: Celgene Corp. – Key customers
Exhibit 68: Eisai Co. Ltd. – Vendor overview
Exhibit 69: Eisai Co. Ltd. – Business segments
Exhibit 70: Eisai Co. Ltd. – Organizational developments
Exhibit 71: Eisai Co. Ltd. – Geographic focus
Exhibit 72: Eisai Co. Ltd. – Segment focus
Exhibit 73: Eisai Co. Ltd. – Key offerings
Exhibit 74: Eisai Co. Ltd. – Key customers
Exhibit 75: F. Hoffmann-La Roche Ltd. – Vendor overview
Exhibit 76: F. Hoffmann-La Roche Ltd. – Business segments
Exhibit 77: F. Hoffmann-La Roche Ltd. – Organizational developments
Exhibit 78: F. Hoffmann-La Roche Ltd. – Geographic focus
Exhibit 79: F. Hoffmann-La Roche Ltd. – Segment focus
Exhibit 80: F. Hoffmann-La Roche Ltd. – Key offerings
Exhibit 81: F. Hoffmann-La Roche Ltd. – Key customers
Exhibit 82: Johnson & Johnson Services, Inc. – Vendor overview
Exhibit 83: Johnson & Johnson Services, Inc. – Business segments
Exhibit 84: Johnson & Johnson Services, Inc. – Organizational developments
Exhibit 85: Johnson & Johnson Services, Inc. – Geographic focus
Exhibit 86: Johnson & Johnson Services, Inc. – Segment focus
Exhibit 87: Johnson & Johnson Services, Inc. – Key offerings
Exhibit 88: Johnson & Johnson Services, Inc. – Key customers
Exhibit 89: Mylan NV – Vendor overview
Exhibit 90: Mylan NV – Product segments
Exhibit 91: Mylan NV – Organizational developments
Exhibit 92: Mylan NV – Geographic focus
Exhibit 93: Mylan NV – Segment focus
Exhibit 94: Mylan NV – Key offerings
Exhibit 95: Mylan NV – Key customers
Exhibit 96: Novartis AG – Vendor overview
Exhibit 97: Novartis AG – Business segments
Exhibit 98: Novartis AG – Organizational developments
Exhibit 99: Novartis AG – Geographic focus
Exhibit 100: Novartis AG – Segment focus
Exhibit 101: Novartis AG – Key offerings
Exhibit 102: Novartis AG – Key customers
Exhibit 103: Pfizer Inc. – Vendor overview
Exhibit 104: Pfizer Inc. – Business segments
Exhibit 105: Pfizer Inc. – Organizational developments
Exhibit 106: Pfizer Inc. – Geographic focus
Exhibit 107: Pfizer Inc. – Segment focus
Exhibit 108: Pfizer Inc. – Key offerings
Exhibit 109: Pfizer Inc. – Key customers
Exhibit 110: Takeda Pharmaceutical Co. Ltd. – Vendor overview
Exhibit 111: Takeda Pharmaceutical Co. Ltd. – Business segments
Exhibit 112: Takeda Pharmaceutical Co. Ltd. – Organizational developments
Exhibit 113: Takeda Pharmaceutical Co. Ltd. – Geographic focus
Exhibit 114: Takeda Pharmaceutical Co. Ltd. – Key offerings
Exhibit 115: Takeda Pharmaceutical Co. Ltd. – Key customers
Exhibit 116: Validation techniques employed for market sizing
Exhibit 117: Definition of market positioning of vendors


【レポート販売概要】

■ タイトル:ベーチェット病治療法の世界市場2019-2023
■ 英文:Behcet's Disease Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023
■ 発行日:2019年8月28日
■ 調査会社:Technavio
■ 商品コード:IRTNTR31936
■ 調査対象地域:グローバル、アジア太平洋、ヨーロッパ、北米、その他
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。